特发性肺纤维化治疗进展

特发性肺纤维化(IPF)是一种慢性炎症性间质性疾病,以肺间质弥漫性渗出、浸润和纤维化为主要病变,是多数肺部疾病的最终结局,晚期引起器官衰竭而死亡。IPF的5年生存率仅50%,确诊后平均存活期为2～4年,近年来发病率不断上升,且缺乏特异有效的药物来治疗。传统的糖皮质激素治疗疗效欠佳,而抗肺纤维化、细胞因子、中医、干细胞移植治疗显示较好的前景。

Development on Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis(IPF)is a chronic inflammatory disorder,the diffuse interstitial lung invasion and fibrosis are the major lesion,IPF is the final result of most pulmonary diseases,organ failure in the late stage causing death.The 5-year survival rate is just 50%,the average survival after confirmed diagnosis is 2-4 years,while the morbidity has been rising continuously in the recent years,specific and effective drugs are still lack.The curative effect of traditional corticosteroids treatment is poor,while good prospects are expected in pulmonary anti-fibrosis treatment,cytokines,traditional Chinese medicine and stem cell transplantation therapy.